Dr. Alexander Calenda

Dr. Mark A. Preston is a urologic surgeon at Brigham and Women’s Hospital and Associate Professor of Surgery at Harvard Medical School. Dr. Preston received his Medical Degree from the University of Ottawa in Canada, where he also completed his residency training in Urology. He completed a three-year accredited fellowship in Urologic Oncology at Massachusetts General Hospital including a Masters of Public Health from the Harvard School of Public Health with a concentration in clinical effectiveness. He is board certified in Urology.Dr. Preston’s clinical interests include urologic oncology (bladder, kidney, prostate and testicular cancer) and minimally invasive surgery. Dr. Preston’s research focuses on the epidemiology of prostate and kidney cancer risk with an emphasis on predictive biomarkers and pharmacoepidemiology. Dr. Preston is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Prostatectomy.

Dr. Mossanen is a graduate of the University of California, Los Angeles (UCLA) in Los Angeles, CA and received his medical degree from the David Geffen School of Medicine at UCLA. He also holds a Master of Public Health from the Harvard T.H. Chan School of Public Health in Boston, MA. Dr. Mossanen completed a residency in Urology from the University of Washington in Seattle, WA followed by a fellowship in Urologic Oncology in the Combined Harvard Urologic Oncology Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Mossanen has been board certified by the American Board of Urology since 2020.His research and clinical interests include: bladder cancer, kidney cancer, kidney masses/cysts, laparoscopic surgery, penile cancer, prostate cancer, robotic surgery, testicular cancer. Dr. Mossanen is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Penile Cancer, Cystectomy, and Nephrectomy.

Dr. Graeme Steele is The Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women’s Hospital, surgical oncologist at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School. He received his medical degree from the University of the Witwatersrand and completed his internship in general surgery at Johannesburg Hospital. He completed residencies in general surgery and urology at the University of Witwatersrand Medical School in Johannesburg, South Africa, and became head of their Department of Urology Medical School.In 1995, he moved to Boston and completed his urology residency at the Harvard Urology Residency Program and received his fellowship in urology at Brigham and Women’s Hospital. Dr. Steele is board certified in urology.The author of numerous clinical publications, Dr. Steele has conducted research studies focusing on benign prostatic hyperplasia, urodynamic evaluation, bladder cancer, urinary cancer and testicular cancer. His clinical specialties include: urinary incontinence, urodynamic studies, urologic oncology and voiding dysfunction. Dr. Steele is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Vasectomy, and Orchiectomy.